Savara/$SVRA
1D1W1MYTD1Y5YMAX
Capital at risk
About Savara
Savara Inc is a clinical-stage biopharmaceutical company. It is focused on rare respiratory diseases. It has one segment specialty pharmaceuticals within the respiratory system. The company's main product candidate, molgramostim, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).
- Ticker
- $SVRA
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 70
- Headquarters
- Yardley, United States
- Website
- www.savarapharma.com
Savara Metrics
BasicAdvanced
$1.4B
-
-$0.58
0.26
-
Price and volume
Market cap
$1.4B
Beta
0.26
52-week high
$7.01
52-week low
$3.34
Average daily volume
1.5M
Financial strength
Current ratio
10.132
Quick ratio
9.994
Long term debt to equity
20.959
Total debt to equity
21.166
Profitability
EBITDA (TTM)
-142.699
Management effectiveness
Return on assets (TTM)
-50.15%
Return on equity (TTM)
-105.48%
Valuation
Price to book
9.78
Price to tangible book (TTM)
10.61
Price to free cash flow (TTM)
-12.041
Free cash flow yield (TTM)
-8.30%
Free cash flow per share (TTM)
-0.459
Growth
Earnings per share change (TTM)
12.69%
3-year earnings per share growth (CAGR)
29.01%
What the Analysts think about Savara
Analyst ratings (Buy, Hold, Sell) for Savara stock.
Analyst projections of the future price of Savara stock.
Bulls say / Bears say
Savara’s 2025 Form 10-K confirms positive topline results from the IMPALA-2 Phase 3 trial of MOLBREEVI in autoimmune PAP, supporting the product’s efficacy ahead of regulatory review (SEC.gov).
The FDA formally filed the MOLBREEVI BLA in February 2026 and granted Priority Review with an August 22, 2026 PDUFA date, indicating accelerated regulatory momentum for the lead candidate (RTTNews).
As of December 31, 2025, Savara held approximately $236 million in cash and short-term investments, plus access to up to $150 million of non-dilutive capital upon FDA approval, providing a well-capitalized runway into product launch (Business Wire).
FDA extended the PDUFA target action date for MOLBREEVI by three months to November 22, 2026, delaying potential approval and compressing the commercial launch timeline (MarketBeat).
Savara incurred net losses of $118.8 million in 2025 and used $101.0 million in operating cash, underscoring a high burn rate that may necessitate dilutive financing if approval or launch is delayed (SEC.gov).
The company’s reliance on a single Phase 3 asset, MOLBREEVI, exposes Savara to binary clinical risk, where failure or further delays would materially impair its financial prospects (SEC.gov).
Data summarised monthly by Lightyear AI. Last updated on 7 Sept 2026.
Savara Financial Performance
Revenues and expenses
Savara Earnings Performance
Company profitability
Upcoming events
No upcoming events
Savara News
AllArticlesVideos
Savara Announces Encore Presentations of Results from the Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (APAP) at the European Respiratory Society (ERS) Congress 2026
Business Wire2 weeks ago
Savara Announces New Employment Inducement Grant
Business Wire3 months ago
Funds containing Savara
AllUSDGBPEUR
Fund name | Fund size | $SVRA weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.08% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.08% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.03% |
SPDR MSCI All Country World IM€SPYI | €7.5B | 0.00% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.